Areas of Investigation
We are actively conducting research in the following diseases:
Graft versus Host Disease (GvHD)
Mallinckrodt is actively engaged in an ongoing clinical trial to assess the efficacy of THERAKOS ECP Immunomodulation™ in steroid-refractory acute GvHD in paediatric patients.
More information about this study is available at: https://clinicaltrials.gov/show/NCT02524847.
Reference: UVADEX™ 20 micrograms/ml solution for blood fraction modification [Professional Leaflet].